Xconomy’s San Francisco Biotech: The Next Generation
6:00pm - 8:45pm
Take a peek at biotech's next generation of leaders, ideas, and strategies through the stories of speakers from three pioneering biotechs that are pushing the status quo:
- Cortexyme is planning Phase 2 trials next year with a new Alzheimer's approach: blocking brain bacteria it believes are responsible for cognitive decline.
- Allogene Therapeutics' founders, previously at Kite Pharma, are advancing a different kind of CAR-T to fight cancer.
- RDMD just launched and is building a health-data repository for rare diseases to help design diagnostics and clinical trials.
CLSA Members receive $25 discount! Please email Marketing@califesciences.org to learn more.
Contact: Nate Leskovic
Contact Email: firstname.lastname@example.org
Genentech Hall at UCSF Mission Bay
600 16th Street
San Francisco, CA 94158